A bispecific T-cell engager (BiTE) antibody construct that binds CD19 on B cells and CD3 on T cells to redirect T-cell cytotoxicity against CD19-positive leukemia cells.
A BiTE antibody construct that simultaneously binds CD19 on B cells and CD3 on T cells, bringing them into proximity to activate T cells and redirect perforin/granzyme-mediated cytotoxicity against CD19-positive leukemia/lymphoma cells in an MHC-independent manner.
Blinatumomab bridges CD3 on T cells to CD19 on target cells, activating T cells to form an immunologic synapse and kill CD19+ cells via perforin/granzyme-mediated apoptosis (MHC-independent).
CD20×CD3 bispecific T‑cell–engaging monoclonal antibody that redirects cytotoxic T cells to kill CD20+ B cells; administered intravenously.
Humanized bispecific monoclonal antibody that binds CD20 on B cells and CD3 on T cells, physically linking them to form an immune synapse and activate T cells, leading to perforin/granzyme-mediated lysis of CD20+ B cells.
Mosunetuzumab links CD20 on B cells to CD3 on T cells, forming an immune synapse that activates T cells to kill CD20+ cells via perforin/granzyme-mediated cytolysis.
First-generation BCR-ABL tyrosine kinase inhibitor used to suppress leukemic proliferation in CML.
ATP-competitive tyrosine kinase inhibitor targeting BCR-ABL (and also PDGFR and KIT), blocking downstream phosphorylation signaling to suppress proliferation and induce apoptosis of malignant cells (e.g., CML; GIST via KIT).
Imatinib directly inhibits KIT’s tyrosine kinase activity (ATP-competitive), shutting down downstream survival/proliferation signaling and inducing cell-cycle arrest and apoptosis in KIT-dependent cells (e.g., GIST).
Anti-CD20 monoclonal antibody that depletes B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes and depletes CD20+ cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis.
Binds CD20 on B cells and triggers complement-dependent cytotoxicity and Fc-mediated ADCC; cross-linking can also induce apoptosis.
Intravenous anti-CD20 monoclonal antibody that depletes CD20+ B cells via ADCC, CDC, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes CD20+ cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
Rituximab binds CD20 on B cells and kills them via Fc-mediated ADCC, complement-dependent cytotoxicity, and direct apoptosis after CD20 crosslinking.